Company Overview and News

2
Eicher Motors Limited - Analysts/Institutional Investor Meet/Con. Call Updates

8h nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
505200 ECQRY EICHERMOT

2
Rohini, Interceptor and Lock Stock: A look at Royal Enfield#39;s three new custom bikes based on 650cc motor

2018-06-19 moneycontrol
In its fourth appearance at the Wheels and Waves festival in France, Eicher Motors controlled Royal Enfield unveiled three of its latest custom build motorcycles developed for the very first time on its yet to be launched twin-cylinder platform.
505200 ECQRY EICHERMOT

35
Weak global cues drag Nifty just below 10,800 amid US-China trade tensions; ICICI up 4%

2018-06-18 moneycontrol
Finally the market settled volatile session on a negative note on Monday, tracking global weakness due to escalated trade tensions between world's biggest economies US and China. The rebound in crude oil prices after trading lower in morning also weighed on investor sentiment.
532617 HCTHY BHRQY 532215 505200 AXISBANK 532281 HDFCBANK BJJQY 500570 BHARTIARTL TATAMOTORS EICHERMOT 500034 INDIGO ECQRY AXB KMBKY IBN JETAIRWAYS 539448 AXBKY 532454 AXBA ICICIBANK BAJFINANCE HDB 532174 500180 HCLTECH KOTAKBANK 500247 TTM

13
Nifty rises 55.90 pts to 4-month high post Trump-Kim meeting

2018-06-12 freepressjournal.in
Mumbai: NSE Nifty rose by 55.90 points to close at four-month high of 10,842.85 on sustained buying mainly in pharma, FMCG, PSU banks, energy and IT sectors amid positive sentiment from global equity markets.
ECQRY INDUSINDBK HINDUNILVR BHRQY 533278 500182 532454 505200 532187 500696 HEROMOTOCO HRTQY BHARTIARTL EICHERMOT CLNDY COALINDIA

2
Eicher Motors Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-06-12 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
505200 ECQRY EICHERMOT

2
‘We’re a bunch of storytellers running a motorcycle company’

2018-06-09 livemint
Rudratej Singh, president of motorcycle maker Royal Enfield, is bullish on the fastest-growing two-wheeler brand, which is propelling the growth of the middleweight motorcycle segment (250cc-750cc) in India and the world over. Cue, the nostalgia alert. The company’s nostalgia play with its classic range—Continental GT and the Pegasus Classic 500, which is inspired by Royal Enfield’s British World War II Flying Flea bikes—has gone a long way in promoting the brand value in more ways than one.
505200 ECQRY EICHERMOT

23
Banks drag Sensex 215 pts, Nifty below 10,700 ahead of RBI policy; Midcap continues to dip

2018-06-04 moneycontrol
The market started off the week on a strong note following positive global cues post better-than-expected US jobs report, but wiped out all its gains within few minutes from opening with the Sensex falling more than 200 points on Monday.
500325 RELIANCE 532978 BHRQY 505200 500470 RIGD HDFCBANK BHARTIARTL EICHERMOT RLNIY ECQRY HINDALCO KMBKY HNDNF 532454 BAJAJFINSV TTST TATASTEEL TATLY HDB 500180 KOTAKBANK 500247 500440

2
Eicher Motors Limited - Analysts/Institutional Investor Meet/Con. Call Updates

2018-06-04 nseindia
The information displayed herein is uploaded by the concerned Company. The said uploaded information is displayed without any verification of adequacy, accuracy and veracity. The Exchange in discharge of its role of dissemination of uploaded information on this website immediately on its receipt. The Company shall be solely responsible and liable for any omission, commission, errors and misrepresentations in the contents of the Information.
505200 ECQRY EICHERMOT

2
VE Commercial Vehicles sales up by 31% in May

2018-06-01 moneycontrol
VE Commercial Vehicles, a joint venture between Volvo Group and Eicher Motors, today reported 30.7 percent increase in sales in May this year to 5,977 units. It had sold 4,573 units in May 2017, VECV said in a statement.
505200 ECQRY EICHERMOT

52
Nifty ends below 10,700, all sectoral indices in the red except Auto; Sensex up 1% for week

2018-06-01 moneycontrol
Benchmark indices closed in the red after volatility on first day of June series Friday as all sectoral indices were in the red barring Auto that outperformed all post May sales data. Continuous correction in midcaps dampened investors sentiment, which led to profit booking after more than 400 points rally on the Sensex in previous session.
BAJAJ-AUTO 500325 RELIANCE 532978 532977 BHRQY 532215 505200 500470 532187 AXISBANK RIGD HDFCBANK HEROMOTOCO BJJQY 500570 BHARTIARTL TATAMOTORS EICHERMOT RLNIY 500034 ECQRY HINDALCO AXB INDUSINDBK KMBKY IBN AXBKY 500182 HNDNF 532454 AXBA ICICIBANK BAJAJFINSV BAJFINANCE TTST TATASTEEL TATLY HDB 532174 500180 KOTAKBANK HRTQY 500247 500440 TTM

Related Articles

ARWR: Arrowhead Pharmaceuticals Analysis and Research Report

2018-06-18 - Asif

Business Arrowhead develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Deemed to be one of the most important recent discoveries in life science with the potential to transform medicine, the discoverers of RNAi were awarded a Nobel Prize in 2006 for their work. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing. In fiscal 2017, Arrowhead refocused its resources on therapeutics that exclusively utilize the company’s Targeted RNAi Molecule (TRiMTM) platform technology. Therapeutics built on the TRiMTM platform have demonstrated high levels of pha...

PRTO: Proteon Therapeutics Analysis and Research Report

2018-06-11 - Asif

Overview Proteon Therapeutics is a late-stage biopharmaceutical company focused on the development of novel, first-in-class pharmaceuticals to address the needs of patients with renal and vascular disease. The company's product candidate, vonapanitase, is a recombinant human elastase that Proteon Therapeutics is developing to improve vascular access outcomes in patients with chronic kidney disease, or CKD, undergoing or planning for hemodialysis, a lifesaving treatment that cannot be conducted without a functioning vascular access. The company believe data from its completed Phase 2 and Phase 3 clinical trials of vonapanitase support that a one-time, local application of investigational vonapanitase during surgical creation of a radiocephalic fistula for hemodialysis may improve fistula use for hemodialysis and secondary patency (time to fistula abandonment), thereby improving patient outcomes and reducing the burden on patients and the healthcare system. Arteriovenous fistu...

GALE: Galena Biopharma Analysis and Research Report

2018-06-11 - Asif

Overview Galena Biopharma is a clinical-stage biopharmaceutical company focused on novel cancer immunotherapeutics for a broad range of cancer indications. The company's lead product candidate, galinpepimut-S, or GPS, is a cancer i unotherapeutic agent licensed from Memorial Sloan Kettering Cancer Center, or MSK, that targets the Wilms tumor 1, or WT1, protein, which is present in 20 or more cancer types. Based on its mechanism of action as a directly immunizing agent, GPS has the potential as a monotherapy or in combination with other immunotherapeutic agents to address a broad spectrum of hematologic, or blood, cancers and solid tumor indications. Phase 2 clinical trials for GPS have been completed and Galena Biopharma has planned Phase 3 clinical trials (pending funding availability) for two indications, acute myeloid leukemia, or AML, and malignant pleural mesothelioma, or MPM. GPS is also in development as a potential treatment for multiple myeloma, or MM, and ovarian can...